

1
2
3
4
5
6
7
8
9
10
11
12

COVID-19 Pandemic: Is Chronic Inflammation a Major Cause of Death?

Albina Tskhay^{1,2}, Alena Yezhova¹, and Kenneth Alibek^{1,2}

¹Locus Fermentation Solutions, LLC, 30500 Aurora Road Suite 180, Solon, 44139, OH, USA.

²FLAASK, LLC, 30500 Aurora Road, Suite 120, Solon, 44139, OH, USA

*Corresponding Author: atskhay@locusfs.com (Albina Tskhay)

13 **Abstract**

14 **Background.** Today humanity is facing another infectious threat: a newly emerging virus SARS-
15 CoV-2 causing COVID-19. It was already described that COVID-19 mortality among elderly
16 people and people with such underlying conditions as obesity, cardiovascular diseases, cancer,
17 chronic respiratory diseases, and diabetes s increased. Dysregulation of the immune responses
18 vital for antiviral defense, which are typical for chronic inflammation, led us to a hypothesis that
19 chronic inflammation is the main risk factor for increased susceptibility and mortality from
20 COVID-19.

21 **Method.** Based on the available information for 126 countries, statistical analysis to find out
22 whether the difference in incidence and mortality within countries can be explained by the
23 existing chronic inflammation among the countries' population, was conducted.

24 **Results.** A positive correlation between the percentage of people dying from chronic
25 noncommunicable diseases and COVID-19 incidence ($p < 0.001$) and mortality ($p < 0.001$) within
26 countries.

27 **Conclusion.** The problem of COVID-19-caused high mortality rate may be a consequence of the
28 high number of people having chronic low-grade inflammation as a precondition, and thus, one
29 of the potential ways to reduce risk of morbidity and mortality is to focus on this widespread
30 health problem, mainly occurring in developed countries and to take corresponding diagnostic,
31 preventative, and treatment measures.

32 **Keywords:** *Chronic noncommunicable diseases; Chronic inflammation; COVID-19; Immune*
33 *system; Immunoaging.*

34 **Introduction**

35 Currently, we are facing a new infectious threat: recently emerged virus SARS-CoV-2 causing
36 coronavirus disease (COVID-19), a disease that has already killed about 270,000 people
37 worldwide in just four months. SARS-CoV-2, a β -CoV, is the seventh coronavirus that has
38 become pathogenic to humans through the process of zoonosis, causing COVID-19, a potentially
39 fatal disease that is of great concern to the global public health and the economic development of
40 every country in the world (Rothan and Byrareddy, 2020). The symptoms of COVID-19
41 infection appear after an incubation period of approximately 3 to 5 days and include fever,
42 cough, fatigue, sputum production, headache, hemoptysis, etc. (Guan et al. 2020).

43 It can be noticed that despite similar countermeasures taken in almost all countries, which
44 include self-isolation, quarantine, social distancing, and wearing face masks, the rates of
45 COVID-19 incidence and mortality differ significantly among countries. There are numerous
46 hypotheses about the underlying causes for the observed differences, but as the research on this
47 continues, it is becoming obvious that the main factor is the immune system function and
48 response to the virus among countries' populations.

49 Specific observation described was increased COVID-19 mortality among elderly people and
50 people with underlying conditions such as obesity, cardiovascular diseases, cancer, chronic
51 respiratory diseases, and diabetes (Novel Coronavirus Pneumonia Emergency Response
52 Epidemiology Team 2020; Lighter et al. 2020). The median age of hospital patients who tested
53 positive for COVID-19 is approximately 63 years (Rothan and Byrareddy, 2020). This situation
54 is not unique, as it is a well-known fact that aging and the abovementioned diseases and
55 conditions are accompanied by chronic inflammation and insufficiency and dysregulation of
56 immune system response (Chung et al. 2019; Zhong and Shi 2019). This results in the immune
57 system's inability to fight infections (Boe et al. 2016; Oh et al. 2019). It is known that elevated
58 levels of proinflammatory mediators (C-reactive protein, tumor necrosis factor, interleukins 1-
59 beta and 6) are associated with infectious disease-caused mortality in these people (Boe et al.
60 2016). Apart from this, the elevation of proinflammatory mediators also negatively affects
61 hemoglobin concentrations, insulin-like growth factor 1 levels, and levels of albumin,
62 micronutrients, and vitamins (Chen et al. 2019).

63 In several works (Meyer 2010; Boe et al; 2016; Oh et al. 2019), the changes in the immune
64 system observed in people with chronic low-grade inflammation were well summarized. Briefly,
65 some of these changes include:

- 66 • Reduced phagocytic activity and number of monocytes and macrophages
- 67 • Reduction in MHC II expression
- 68 • Altered cytokines production
- 69 • Altered TLR expression and signaling
- 70 • Decreased natural killer (NK) cells cytotoxic activity
- 71 • Dysfunctional neutrophils
- 72 • Decreased number of naïve T and B cells

- 73 • Increased accumulation of senescent T cells
- 74 • Diminished response of T cells to new antigens

75 The combination of these immune abnormalities is named immuno-aging. This condition is
76 characterized by dysregulation of both the innate and adaptive immune system, and the
77 malfunctioning of the immune system in the respiratory system of these individuals is especially
78 well described. Specifically, elevated levels of proinflammatory mediators contribute to
79 diminished pulmonary function and dysregulate immune responses to respiratory infections
80 which are characterized by reduced mucociliary clearance, upregulation of proteins participating
81 in the attachment of pathogens to epithelial cells of the respiratory system, reduction of toll-like
82 receptors (TLR) expression on lung cells, etc. (Boe et al. 2016). In addition to the numerous
83 immune system alterations increasing the susceptibility to respiratory infections, existing lung
84 inflammatory responses upon new infection additionally increase susceptibility to bacterial co-
85 infections such as *Streptococcus pneumoniae* and others (Aguilera and Lenz 2020).

86 As a matter of fact, the initial immune response plays a crucial role in the COVID-19 outcome.
87 Cells generally respond to virus infection by mounting an innate antiviral response to limit the
88 spread of the infection and aid in inducing an adaptive immune response that will eventually
89 clear the virus. For instance, coronaviruses exploit the toll-like and some other receptors for
90 initial attachment. Activation of one or more of these sensors generally leads to the activation of
91 the transcription factors interferon (IFN)-regulatory factors 3 and 7 and NF- κ B. These stimulate
92 the expression and excretion of type-I IFN and pro-inflammatory cytokines, which in turn
93 activate the JAK-STAT signaling cascade that induces the expression of antiviral interferon-
94 stimulated genes (ISGs). This ultimately results in an antiviral state of the infected and
95 neighboring cells. ISGs were shown to target virtually all steps of the viral cycle in order to
96 restrict viral replication (de Wilde et al., 2018). However, as it was found, the TLRs are
97 downregulated in the condition of immunoaging (Oh et al. 2019). At the same time, the severity
98 of coronaviral infection depends on the IFN response timing relative to infection. Immediate
99 production of one's own IFN-I or exogenous IFN administration can result in clearance of the
100 virus or a delayed and slowed multiplication, leading either to the termination of infection by the
101 innate mechanisms or to the elimination of the virus by timely or already formed mechanisms of
102 specific immunity. On the other hand, a delay in IFN-I response will most likely result in the

103 increase of pro-inflammatory cytokine production and more severe outcomes (Channappanavar
104 et al. 2019).

105 Dysregulated immune responses could potentially drive the COVID-19 hallmark syndromes such
106 as acute respiratory distress syndrome (ARDS), cytokine release syndrome (CRS), and
107 lymphopenia. The initial mode of viral pathogen-associated signal (PAMP) recognition by innate
108 cells has a major impact on downstream myeloid signaling and cytokine secretion. Significantly
109 elevated systemic levels of pro-inflammatory cytokine IL-6 have been reported in several
110 COVID-19 patient cohorts and shown to correlate with disease severity. Increased IL-6 can also
111 be associated with higher levels of IL-2, IL-7, IFN- γ , and GM-CSF as seen in secondary
112 hemophagocytic lymphohistiocytosis. In response to viral infections, mononuclear phagocytes
113 (MNP) drive interleukin, and IFN-I and IFN-III production, resulting in inflammasome
114 activation, induction of pathogenic Th1 and Th17 cell responses, recruitment of effector immune
115 cells and cytokine release syndrome pathology (Vabret et al., 2020).

116 Dysregulation of the immune responses vital for antiviral defense, which are typical for chronic
117 inflammation, led us to the hypothesis that chronic inflammation is the main risk factor for
118 increased COVID-19 morbidity and mortality. Based on available information, in this work, we
119 aimed to conduct a statistical analysis to find out whether the difference in incidence and
120 mortality within countries can be predominantly explained by the chronic inflammation among
121 the countries' population.

122 **Methods**

123 To assess the chronic inflammation incidence among populations, the data from the World
124 Health Organization available from <https://www.who.int/nmh/countries/en/> was used. In these
125 country profiles collected in 2018, the data on the percentage of people dying of chronic diseases
126 are reported. Countries for which these data were not reported were excluded from the report.
127 Data of COVID-19 cases and death per million of population for each country were obtained
128 from <https://www.worldometers.info/coronavirus/> in the afternoon (EST) of May 2nd, 2020.
129 Countries with the data absent were excluded from the analyses. The information about the
130 incidence of COVID-19 and mortality from these diseases as well as the information about the
131 death rate due to chronic noncommunicable diseases was available for 126 countries.

132 Pearson’s and Spearman’s correlation statistical analyses were conducted using JASP (2020).
 133 For more reliable results, additionally, Vovk-Sellke Maximum p-ratio (VS-MPR) also was
 134 included in the analyses (Sellke et al. 2011).

135 **Results**

136 The statistically significant correlation between the percentage of people dying of chronic
 137 diseases and the number of COVID-19 caused deaths per million of population in each country
 138 as a result of using both Pearson’s and Spearman’s correlations methods with P-value <0.001
 139 and very high VS-MRPs (Tables 1 and 2). It was noted that the COVID-19 mortality rate is not
 140 increasing gradually with the chronic diseases mortality but rather there is a sharp increase
 141 observed in the countries where chronic diseases mortality is higher than 80% (Figure 1a)

Pearson's Correlations

	n	Pearson's r	p	Lower 95% CI	Upper 95% CI	VS-MPR [†]
NCD - Deaths/1M	126	0.281	0.001	0.112	0.435	39.076

[†] Vovk-Sellke Maximum *p* -Ratio: Based on the *p*-value, the maximum possible odds in favor of H₁ over H₀ equals 1/(-e *p* log(*p*)) for *p* ≤ .37 (Sellke et al. 2001).

142 **Table 1.** Pearson's correlations between noncommunicable chronic diseases death rate and
 143 COVID-19 mortality among countries.

Spearman's Correlations

	n	Spearman's rho	P	Lower 95% CI	Upper 95% CI	VS-MPR
NCD - Deaths/1M	126	0.628	< .001	0.509	0.724	3.210e ¹²

144 **Table 2.** Pearson's and Spearman’s correlations between noncommunicable chronic diseases death
 145 rate and COVID-19 mortality among countries.

146
 147 The statistically significant correlation between the percentage of people dying of chronic
 148 diseases and the incidence of COVID-19 per million of population in each country was a result
 149 of using only Pearson’s correlations method with a p-value <0.001 and very high VS-MRP as
 150 well (Table 3). In Figure 1b, it can be seen that the incidence is gradually increasing with the
 151 percentage of people having chronic diseases with considerable difference observed when the
 152 percentage of people dying of chronic diseases is 70% and higher (mostly high-income
 153 countries).

Pearson's Correlations

	n	Pearson's r	p	Lower 95% CI	Upper 95% CI	VS-MPR†
NCD - Tot Cases/1M	126	0.304	< .001	0.136	0.454	89.189

154 **Table 3.** Pearson's correlations between noncommunicable chronic diseases death rate and
155 COVID-19 incidence among countries.

156

157 **Discussion**

158 Chronic noncommunicable diseases are a known risk factor for susceptibility to COVID-19 and
159 mortality from this disease. Additionally, statistical analysis showed that overall patterns of
160 incidence and mortality in countries also may depend on the chronic diseases' prevalence. This
161 could mean that most COVID-19 victims even if they are not affected by cancer, cardiovascular
162 diseases, or other comorbidities associated with increased COVID-19 mortality, are already
163 affected by chronic low-grade inflammation and resulting from this, immunoaging. It is not
164 widespread knowledge, but a large proportion of population are carriers of chronic respiratory
165 bacterial infections such as *Neisseria meningitidis*, *Haemophilus influenzae*, and *Staphylococcus*
166 *aureus*. (Bhatta et al. 2014; Peterson et al. 2014). For instance, in some countries, the overall
167 asymptomatic chronic carriage of *N. meningitidis*, a respiratory pathogen, reaches 60% to 70%
168 (Bidmos et al. 2011; Rizek et al. 2016). This is especially important to pay attention to because
169 it was reported that COVID-19 patients with higher neutrophil-to-lymphocyte ratio usually tend
170 to have higher severity and mortality rate (Liu et al. 2020). While increased neutrophils and
171 decreased lymphocytes are more typical for bacterial infection, this indicates possible bacterial-
172 viral co-infection which increases the risk of a fatal outcome for patients with a pre-existing
173 chronic bacterial infection.

174 Chronic inflammation is also likely to create another challenge for fighting COVID-19.

175 Currently, the main attempts on finding a solution are focused on vaccine development while it is
176 known that chronic inflammation and resulting immune system dysregulation reduce the
177 immunogenicity of vaccines. As it was already shown in animals in the case of SARS-CoV,
178 similar coronavirus infection leading to atypical pneumonia, young mice immunized with anti-
179 SARS vaccine appeared to be protected, but aged mice (the ones with immunoaging) infected
180 with SARS demonstrated more severe symptoms than unvaccinated mice (Deming et al. 2006).

181 The problem of chronic diseases is not just a factor affecting survival from COVID-19, but also
182 overall longevity of populations since chronic noncommunicable diseases are the leading death

183 cause in most countries. “Currently, chronic diseases are the leading cause of death in the world
184 and their impact is steadily growing. Approximately 17 million people die prematurely each year
185 as a result of the global epidemic of chronic disease” (WHO 2019).

186 This indicates a critical need for searching for solutions to reduce chronic inflammation.
187 Although chronic diseases we discuss here are also called chronic noncommunicable diseases,
188 there is still an accumulated knowledge on the role of chronic persistent and latent bacterial and
189 viral infections in these diseases (Knobler 2004; O’Connor et al. 2006; Ogoina and
190 Onyemelukwe 2009).

191 Numerous studies, case reports, and clinical trials have already shown that the treatment of
192 infections may have a highly beneficial health effect in relation to noncommunicable diseases.
193 For instance, antiviral therapy inhibited tumors in cases of lymphoma and leukemia (Abdulkarim
194 and Bourhis 2001; Hermine et al. 1995). MALT lymphoma and gastric cancer cells proliferation,
195 in many cases caused by *H. pylori*, can be eliminated or reduced in most cases when treated with
196 antibacterial therapy (Andriani et al. 2009; Tang et al. 2014). Antiviral drugs were shown to
197 reduce cell proliferation in breast cancer (Pettersson et al. 2011). Treatment of glioblastoma
198 patients with an antiviral drug was shown to reduce tumor growth by 72%, increase the number
199 of patients with 2-year survival by 72% and increase life expectancy by 42 months (13.5 vs 56
200 months) (Söderberg-Nauclér et al. 2013). 80% of hepatocellular carcinomas are associated with
201 HBV and HCV, and every year 500,000 lives can be saved if these viruses are treated using
202 antiviral therapy (Alibek et al. 2012). Antiviral drugs were shown to decrease tumor size and to
203 induce apoptosis in HPV-caused nasopharyngeal cancer (Yoshizaki et al. 2008). In patients with
204 diabetes type 2, the use of antibiotics improved glycemic control, decreased the levels of
205 inflammatory markers, and reduced the severity of insulin resistance (Bharti et al. 2013). As
206 well, it was shown that antibacterial treatment soon after the infection reduced the risk of
207 atherosclerosis development by 85% (Fong 2000). However, despite these findings, none of
208 these noncommunicable diseases are treated using antimicrobial therapies.

209 Realizing that we cannot guarantee that our suggestions can help in solving all problems, our
210 efforts can be focused on three directions with some or high probability of reducing risks:
211 1. Clinics in many countries do not include main inflammatory markers (such as C-reactive
212 protein) to the routine tests (Bazeley et al. 2011). The widespread testing of known markers and

213 the creation of new diagnostic approaches and methods to assess systemic inflammation or its
214 individual branches will help to prevent the emergence of chronic disease or allow it to be treated
215 in the early stages.

216 Even though there is no universally established criterium, these tests below can help in detecting
217 the pro-inflammatory state.

- 218 • Blood and/or saliva
 - 219 ○ C-reactive protein
 - 220 ○ IL-6
 - 221 ○ Ferritin level
 - 222 ○ TNF-alpha
 - 223 ○ Fibrinogen level
- 224 • Blood:
 - 225 ○ Hemoglobin A1C
 - 226 ○ Erythrocyte count and sedimentation rate
 - 227 ○ Lymphocyte count
 - 228 ○ Neutrophil count
 - 229 ○ White blood cell count
 - 230 ○ Creatine kinase

231 2. There is a need to create a new understanding and principles of treatment with existing and
232 new antibacterial and antiviral drugs, as the concept of short-term use of both should be revised.
233 Chronic infections cannot be cured by short treatment courses. Moreover, in view of the so-
234 called poly-infection or burden of infections, it is necessary to begin to consider the possibility of
235 combined therapies, such as antibacterial and antiviral drugs administered simultaneously.

236 3. Despite the already relatively well-established understanding of chronic inflammation,
237 medical science, and practice for the treatment of chronic inflammation still do not exist. The list
238 of drugs for the treatment of these pathologies is very narrow, and the creation of integrated
239 approaches to anti-inflammatory therapy combined with effective anti-infectious treatment can
240 significantly prevent premature deaths promoted by the abovementioned conditions.

241 **Conclusion**

242 Although life expectancy in high-income countries is significantly higher than in the developing
243 ones, there is still a health problem to be targeted to increase longevity and improve life quality –
244 chronic inflammation. The COVID-19 pandemic revealed an underestimation of chronic
245 inflammation playing role in increased mortality in the majority of developed countries, and this
246 problem is very likely to be detrimental for survival during the COVID-19 pandemic. In order to
247 reduce the risk of death resulting from COVID-19 and other unexpected health threats, there is a
248 necessity to reconsider more comprehensive methods of chronic inflammation diagnosis and
249 prevention and treatment of these conditions.

250 **Acknowledgments**

251 We are grateful to Andrew Lefkowitz, CEO and chairman of FLAASK, LLC, for his financial,
252 administrative, and moral support provided for this work.

253 **Declarations**

254 Ethics approval and consent to participate – not applicable

255 Consent for publications – not applicable

256 Competing interests - authors have no competing financial, professional, or personal interests
257 that might have influenced the performance or presentation of the work described in this
258 manuscript.

259 Funding: the study was funded by FLAASK, LLC, grant #9. KA and AT are employees of
260 FLAASK, LLC

261 **References**

- 262 Abdulkarim B, Bourhis J. 2001. Antiviral approaches for cancers related to epstein-barr virus
263 and human papillomavirus. *Lancet Oncol* 2(10):622-30. <https://doi.org/10.1016/S1470->
264 2045(01)00520-4.
- 265 Aguilera ER and Lenz LL. 2020 Inflammation as a Modulator of Host Susceptibility to
266 Pulmonary Influenza, Pneumococcal, and Co-Infections. *Front. Immunol.* 11:105. doi:
267 10.3389/fimmu.2020.00105
- 268 Alibek K, Bekmurzayeva A, Mussabekova A. Using antimicrobial adjuvant therapy in cancer
269 treatment: a review. *Infect Agents Cancer.* 2010;7:33. <https://doi.org/10.1186/1750-9378-7-33>.
- 270 Andriani A, Miedico A, Tedeschi L, Patti C, Di Raimondo F, Leone M, Schinocca L, Romanelli
271 A, Bonanno G, Linea C, Giustini M. 2009. Management and long-term follow-up of early stage
272 h. pylori-associated gastric malt-lymphoma in clinical practice: An italian, multicentre study. *Dig*
273 *Liver Dis.* 41(7):467-73. <https://doi.org/10.1016/j.dld.2008.09.009>.
- 274 Bazeley J, Bieber B, Li Y, Morgenstern H, de Sequera P, Combe C, ... Robinson BM. 2011. C-
275 Reactive Protein and Prediction of 1-Year Mortality in Prevalent Hemodialysis Patients. *Clinical*
276 *Journal of the American Society of Nephrology,* 6(10), 2452–2461. doi:10.2215/cjn.00710111
- 277 Bharti P, Katagiri S, Nitta H, Nagasawa T, Kobayashi H, Takeuchi Y, Izumi Y. 2013.
278 Periodontal treatment with topical antibiotics improves glycemic control in association with
279 elevated serum adiponectin in patients with type 2 diabetes mellitus. *Obesity Research &*
280 *Clinical Practice;* 7(2):129–38. <https://doi.org/10.1016/j.orcp.2011.11.005>.
- 281 Bhatta DR, Gokhale S, Sharma AL, Gupta U, Gaur A, Gowda S, Raut S, Thapa S, Khadka R.
282 2014. Carrier state of Haemophilus influenzae type b (Hib), Streptococcus pneumoniae,
283 Streptococcus pyogenes, Neisseria meningitidis and Corynebacterium diphtheriae among school
284 children in Pokhara, Nepal. *Asian Pac J Trop Dis.* Feb;4(1):45–9. doi: 10.1016/S2222-
285 1808(14)60312-1. PMID: PMC4027360.
- 286 Bidmos FA, Neal KR, Oldfield NJ, et al. 2011. Persistence, replacement, and rapid clonal
287 expansion of meningococcal carriage isolates in a 2008 university student cohort. *J Clin*
288 *Microbiol;* 49(2):506–12.

- 289 Boe DM, Boule LA, & Kovacs EJ. 2016. Innate immune responses in the ageing lung. *Clinical*
290 *& Experimental Immunology*, 187(1), 16–25. doi:10.1111/cei.12881
- 291 Channappanavar R, Fehr AR, Zheng J, et al. 2019. IFN-I response timing relative to virus
292 replication determines MERS coronavirus infection outcomes. *J Clin Invest*; 129(9):3625-39.
293 doi: 10.1172/jci126363
- 294 Chen Y, Liu S, Leng SX. 2019. Chronic Low-grade Inflammatory Phenotype (CLIP) and
295 Senescent Immune Dysregulation. *Clin Ther.* (3):400-409
- 296 Chung HY, Kim DH, Lee EK, Chung KW, Chung S, Lee B, Seo AY, Chung JH, Jung YS, Im E,
297 Lee J, Kim ND, Choi YJ, Im DS, Yu BP. 2019. Redefining Chronic Inflammation in Aging and
298 Age-Related Diseases: Proposal of the Senoinflammation Concept. *Aging Dis.* 10(2):367-382.
299 doi: 10.14336/AD.2018.0324.
- 300 de Wilde AH, Snijder EJ, Kikkert M, van Hemert MJ. 2018. Host Factors in Coronavirus
301 Replication. *Curr Top Microbiol Immunol.* 419:1-42. doi:10.1007/82_2017_25
- 302 Deming D, Sheahan T, Heise M, Yount B, Davis N, Sims A, Baric R. 2006. Vaccine Efficacy in
303 Senescent Mice Challenged with Recombinant SARS-CoV Bearing Epidemic and Zoonotic
304 Spike Variants. *PLoS Medicine.* 3(12), e525. doi:10.1371/journal.pmed.0030525
- 305 Fong IW. 2000. Antibiotics Effects in a Rabbit Model of Chlamydia pneumoniae–Induced
306 Atherosclerosis. *J Infect Dis.* 181(s3):S514–8. <https://doi.org/10.1086/315607>.
- 307 Guan WJ, Ni ZY, Hu Y, et al. 2020. Clinical characteristics of 2019 novel coronavirus infection
308 in China.
- 309 Hermine O, Bouscary D, Gessain A, Turlure P, Leblond V, Franck N, Buzynveil A, Rio B,
310 Macintyre E, Dreyfus F, Bazarbachi A. 1995. Brief report - treatment of adult t-cell leukemia-
311 lymphoma with zidovudine and interferon-alfa. *N Engl J Med.* 332(26):1749-51. DOI:
312 10.1056/NEJM199506293322604.
- 313 JASP Team. 2020. JASP (Version 0.12.2)[Computer software].
- 314 Knobler S. 2004. The infectious etiology of chronic diseases. Washington, D.C.: National
315 Academies Press.

- 316 Lighter J, Phillips M, Hochman S, Sterling S, Johnson D, Francois F, Stachel A. 2020. Obesity
317 in patients younger than 60 years is a risk factor for Covid-19 hospital admission. Infectious
318 Diseases Society of America
- 319 Liu J, Liu Y, Xiang P, Pu L, Xiong H, Li C, Zhang M, Tan J, Xu Y, Song R, Song M, Wang L,
320 Zhang W, Han B, Yang L, Wang X, Zhou G, Zhang T, Li B, Wang Y, Chen Z, Wang X. 2020.
321 Neutrophil-to-Lymphocyte Ratio Predicts Severe Illness Patients with 2019 Novel Coronavirus
322 in the Early Stage medRxiv 2020.02.10.20021584; <https://doi.org/10.1101/2020.02.10.20021584>
- 323 Meyer K. 2010. The Role of Immunity and Inflammation in Lung Senescence and Susceptibility
324 to Infection in the Elderly. *Seminars in Respiratory and Critical Care Medicine*, 31(05), 561–
325 574. doi:10.1055/s-0030-1265897
- 326 Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. 2020. The
327 Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-
328 19) in China. *Zhonghua Liu Xing Bing Xue Za Zhi*; 41(2):145–151.
329 DOI:10.3760/cma.j.issn.0254-6450.2020.02.003.
- 330 O'Connor SM, Taylor CE, Hughes JM. 2006. Emerging infectious determinants of chronic
331 diseases. *Emerg Infect Dis*. 12(7):1051-7. doi: 10.3201/eid1207.060037. PMID: 16836820;
332 PMCID: PMC3291059.
- 333 Ogoina D, & Onyemelukwe GC. 2009. The role of infections in the emergence of non-
334 communicable diseases (NCDs): Compelling needs for novel strategies in the developing world.
335 *Journal of Infection and Public Health*, 2(1), 14–29. doi:10.1016/j.jiph.2009.02.001
- 336 Oh SJ, Lee JK, Shin OS. 2019 Aging and the Immune System: the Impact of Immunosenescence
337 on Viral Infection, Immunity and Vaccine Immunogenicity. *Immune Netw*. Dec;19(6):e37.
- 338 Peterson ME, Li Y, Shanks H on behalf of Meningococcal Carriage Group, et al. 2019.
339 Serogroup-specific meningococcal carriage by age group: a systematic review and meta-analysis.
340 *BMJ Open*; 9:e024343. doi: 10.1136/bmjopen-2018-024343
- 341 Pettersson F, Yau C, Dobocan MC, Culjkovic-Kraljacic B, Retrouvay H, Puckett R, Flores LM,
342 Krop IE, Rousseau C, Cocolakis E, Borden KLB. 2011. Ribavirin treatment effects on breast

- 343 cancers overexpressing eif4e, biomarker with prognostic specificity for luminal b-type breast
344 cancer. *Clin Cancer Res*; 17(9):2874-84. doi: 10.1158/1078-0432.CCR-10-2334.
- 345 Rizek CF, Luiz AM, De Assis GR, et al. 2016. Comparison of methods to identify *Neisseria*
346 meningitidis in asymptomatic carriers. *Revista do Instituto de Medicina Tropical de Sao Paulo*;
347 58(no pagination).
- 348 Rothan H, Byrareddy SN. 2020. The Epidemiology and Pathogenesis of Coronavirus Disease
349 (COVID-19) Outbreak. *J Autoimmun.* 109:102433. doi:10.1016/j.jaut.2020.102433
- 350 Sellke T, Bayarri MJ, Berger JO. 2001. Calibration of p values for testing precise null
351 hypotheses. *The American Statistician.* 55:62–71.
- 352 Söderberg-Nauclér C, Rahbar A, and Stragliotto G. 2013. Survival in patients with glioblastoma
353 receiving valganciclovir. *N Engl J Med.* 369(10):985–6. doi:10.1056/nejmc1302145.
- 354 Tang C, Yang L, Jiang X, Xu C, Wang M, Wang Q, Cui H. 2014. Antibiotic drug tigecycline
355 inhibited cell proliferation and induced autophagy in gastric cancer cells. *Biochem Biophys Res*
356 *Comm.* 446(1):105–12. <https://doi.org/10.1016/j.bbrc.2014.02.043>.
- 357 Vabret N, Britton G, Gruber C, Hegde S, Kim J, & Kuksin M. et al. 2020. Immunology of
358 COVID-19: current state of the science. *Immunity.* doi: 10.1016/j.immuni.2020.05.002
- 359 World Health Organization. 2018. Noncommunicable diseases country profiles 2018. Retrieved
360 12 May 2020, from <https://www.who.int/nmh/countries/en/>
- 361 World Health Organization (WHO). 2019. "Stop the global epidemic of chronic disease".
362 Available from <https://www.who.int/mediacentre/news/releases/2005/pr47/en/>
- 363 Worldometer. 2020. Coronavirus Update (Live - Retrieved 12 May 2020, from
364 <https://www.worldometers.info/coronavirus/>
- 365 Yoshizaki T, Wakisaka N, Kondo S, Muroso S, Shimizu Y, Nakashima M, Tsuji A, Furukawa
366 M. 2008. Treatment of locally recurrent Epstein-Barr virus-associated nasopharyngeal carcinoma
367 using the anti-viral agent cidofovir. *J Med Virol*; 80(5):879-82.
368 <https://doi.org/10.1002/jmv.21165>.

369 Zhong J, Shi G. 2019. Editorial: Regulation of Inflammation in Chronic Disease. *Frontiers In*
370 *Immunology*, 10. doi: 10.3389/fimmu.2019.00737




Figure 1. Graphical representation of correlations between noncommunicable chronic diseases death rate and COVID-19 mortality (a) and incidence (b) among countries.